<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-91e9c5c4=""><div class="content_outer_container" data-v-91e9c5c4=""><div class="share_preview_container" data-v-91e9c5c4=""><div class="dialog_list" data-v-91e9c5c4=""><div class="dialog_item" data-v-91e9c5c4=""><div class="dialog_question fir_dialog_question" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""><h1 class="fir_question_content" data-v-91e9c5c4="">
                                    How did ZyVersa Therapeutics' expenses trend in Q4 2024?
                                </h1> <div class="user_slot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-91e9c5c4=""> <span class="user_desction" data-v-91e9c5c4="">
                                        
                                        5/9/2025 08:14am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-91e9c5c4="">In Q4 2024, ZyVersa Therapeutics saw a significant increase in Research and Development (R&amp;D) expenses, which rose to $121,245. This indicates a strong focus on product development and innovation. However, there was no corresponding data for Change in Property and Equipment, which suggests that the company may not have made significant investments in physical assets during this period.


|code|Ticker|Name|Date|R&amp;D Expenses|market_code|
|---|---|---|---|---|---|
|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q1|512937|186|
|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q2|709049|186|
|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q3|436043|186|
|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q4|121245|186|

</div> <div class="dialog_answer" data-v-91e9c5c4=""><div class="dialog_content" data-v-91e9c5c4=""> <div class="answer_robot" data-v-91e9c5c4=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/AIme.ae832fb.png" alt="robot" class="avatar" data-v-91e9c5c4=""> <div class="user_name" data-v-91e9c5c4=""></div></div> <div class="question_content" data-v-91e9c5c4=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-4e97ba8a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-4e97ba8a=""> <div class="recommend-part" data-v-7790c618="" data-v-4e97ba8a=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao){return {layout:"default",data:[{noData:c,currentQuestion:h,textDescription:R,comeFrom:"AInvestShareLink",events:[],answerSource:w}],fetch:{},error:n,state:{sharePreviewModule:{loadJgySuccess:e,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:g,agent_id:a,output_media_info:[],task_id:a,language:a,source:w,cache_builder:a,reply_action:"Answer",execute_mode:D,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did ZyVersa Therapeutics' expenses trend in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did ZyVersa Therapeutics' expenses trend in Q4 2024?\",\"user_id\":\"dp95203100\",\"user_name\":\"\",\"trace_id\":\"b823eed7-4562-4496-a34f-fc7bb25c1827\",\"session_id\":\"b823eed7-4562-4496-a34f-fc7bb25c1827\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:i,text:"1 results found:\n|stock code|stock name|Last Price|Last Change|R&D Expenses[20241231]|Change in Property and Equipment[20241231]|Report End Date|\n|---|---|---|---|---|---|---|\n|ZVSA|ZyVersa Therapeutics|$0.57|-16.59%|$121245||20241231|\n",query_data:{number:g,title:E,query_type:i,condition:a,model_sql:S,data_ext_params:{merge_repeat:c,expand_index:b,data_add:g,add_index:e}}}],answer_chain_name:T,agent_mode:U,native_answer:a,come_from:a,text_answer:R,trace_id:o,cost:16778,event_names:a,question:h,fallback_type:V,input_type:"typewrite",fall_back_reason:{fall_back_type:V,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:o,first_return_cost:2923,cache_type:"no_cache",question_id:o,transfer_question:h,signal_type:"ON_COMPLETE",start_time:F,remote_svc:w,slots:[],answer_type:D,user_id:G,skill_name:H},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:o,session_id:o,user_id:G,question:h,source:w,raw_question:h,version:"3.4.1",action_name:H,nlu:{entity:[{type:W,value:p,market:j}]},output_time:F,deep_research:c,deep_thinking:c,agent_mode:U},extra:{}},{answer_path:x,section:{id:y,info_texts:["Thinking"],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:x,section:{id:y,info_texts:["Querying Stock: ZVSA R&D Expenses, SG&A Expenses, CAPEX in Q4 2024"],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:E,thought:"The user seeks to analyze ZVSA's Q4 2024 expenses. I should focus on its Q4 2024 R&D, SG&A, and CAPEX data. I will use FinQuery for the data mentioned above."}},{answer_path:d,section:{id:q,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:q,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:x,section:{id:y,info_texts:["Generating Answer"],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:r,voice_txt:"In",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:r,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:E,query_type:i,trace_data:a,index:g,model_sql:S,data_ext_params:{merge_repeat:c,expand_index:b,data_add:g,add_index:e},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:r,voice_txt:". This",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:s,market_id:j,name:m,domain:W},pos:12,section_id:l,txt:m,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:q,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:q,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:q,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:r,voice_txt:"\n",text_answer:Z,rich_text:Z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:_,choice:[],result_page:{components:[{uuid:"b76798f07db12640",config:{score:16,show_type:$,scoreRuleNames:"value_unit;data_size;",showDataZoom:b,show_type_id:101,title:"柱状图",render:{x:t,y:[A]},title_config:{config:{display:b,display2:c,txt_style:e,url:a},data:{h1:aa,h2:a},show_type:I}},data:{chunks_info:"[]",code_count:g,columns:[{index_name:J,key:J,label:"hq_code",source:K,type:f},{domain:L,feKey:M,index_name:M,key:M,label:J,origin_index:"stock code",source:K,type:f,unit:a},{domain:L,feKey:N,index_name:N,key:N,label:"name",origin_index:"stock name",source:K,type:f,unit:a},{feKey:t,index_name:t,key:t,label:"date",origin_index:t,type:"DATE"},{domain:L,feKey:A,index_name:A,key:A,label:a,source:a,timestamp:a,type:"DOUBLE",unit:"USD"},{index_name:ab,key:ab,type:f}],condition:"[{\"sonSize\":4,\"opName\":\"and\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"indexProperties\":[\"EQUAL ZVSA.O\"],\"indexPropertiesMap\":{\"EQUAL\":\"ZVSA.O\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":2,\"opName\":\"or\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@R\\u0026D Expenses\",\"indexProperties\":[\"起始交易日期 20240101\",\"截止交易日期 20241231\"],\"indexPropertiesMap\":{\"起始交易日期\":\"20240101\",\"截止交易日期\":\"20241231\"},\"domain\":\"abs_国际美股领域\",\"relatedSize\":0},{\"sonSize\":0,\"indexName\":\"国际美股@stock code\",\"domain\":\"abs_国际美股领域\",\"relatedSize\":0}]",dataSize:4,datas:[{code:s,"R&D Expenses":512937,Ticker:p,market_code:j,Date:"2024 Q1",Name:m},{code:s,"R&D Expenses":709049,Ticker:p,market_code:j,Date:"2024 Q2",Name:m},{code:s,"R&D Expenses":436043,Ticker:p,market_code:j,Date:"2024 Q3",Name:m},{code:s,"R&D Expenses":121245,Ticker:p,market_code:j,Date:"2024 Q4",Name:m}],meta:{extra:{}},row_count:g,status_code:e,status_msg:"ok"},category:"generic",chart_type:"bar",show_type:$,title_config:{config:{display:b,display2:c,txt_style:e,url:a},data:{h1:aa,h2:a},show_type:I},support_refresh:b,data_config:{query:a,query_type:i,data_ext_params:{}}}],global:{query_type:i},page:{language:a,layout:{layout_data:"[{\"children\":[],\"showType\":\"bar3\",\"uuid\":\"b76798f07db12640\"}]"},render_for:O},data_config:{query:a,query_type:i,data_ext_params:{}}},tag_info_list:[],is_last:c,uuid:"067c63bb-5202-46f6-bc20-6b6e9da64c87"},logs:[],extra:{}},{answer_path:d,section:{id:l,info_texts:[],show_type:r,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:x,section:{id:y,info_texts:["Completed"],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:_,choice:[{display_text:u,query_text:u,trace_info:{item_id:"2ed47fc2938dacb65f23ec0f2aaafa3f",item_type:B,item_name:u,rec_info:ac}},{display_text:v,query_text:v,trace_info:{item_id:"f89fe3cfb641e8d985ce8819c73d8946",item_type:B,item_name:v,rec_info:ad}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:I,data:{h1:a,h2:a},config:{display:c,txt_style:e,type:"1",display2:c,url:a}},request_config:[{source_type:3,related_name:ae}],puuid:P,tag:a,category:"custom",uuid:af}],global:{urp_static_data:[{name:ae,value:{status_code:e,columns:[{type:f,index_name:ag,key:ag},{type:f,index_name:ah,key:ah},{type:f,index_name:ai,key:ai},{type:f,index_name:aj,key:aj},{type:f,index_name:ak,key:ak}],datas:[{send_text:u,item_type:B,rec_info:ac,display_text:u,rec_reason:a},{send_text:v,item_type:B,rec_info:ad,display_text:v,rec_reason:a}],dataSize:2,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:al,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:C,"min-height":"100%",position:am,height:C},isMaterial:c,id:al,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:e,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:Q,componentUuid:af,script:[{name:an,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:Q,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:Q},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:C,position:am,height:C},isMaterial:b,_id:19,id:an,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:O,voice_txt:a,tracking_info:{},uuid:P},order:{is_auto:c,render_for:O,chart_type:"command",puuid:P}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:k,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:H,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:D,answer_chain_name:T},is_deep_research:c,deep_thinking:c,create_time:1746749665303},is_last:b}],questionItem:{data:{qStr:h,encodeFlag:c,imageData:n,docsData:[],quoteData:n},tplType:"question"},events:[],agentId:a}],userId:G,userName:a,startTime:F,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:n,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],traceTableData:n,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-zyversa-therapeutics-expenses-trend-in-q4-2024-7022b1\u002F",config:{_app:{basePath:ao,assetsPath:ao,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer",0,"STR",1,"How did ZyVersa Therapeutics' expenses trend in Q4 2024?","intusstock","186","signal",2001,"ZyVersa Therapeutics",null,"b823eed7-4562-4496-a34f-fc7bb25c1827","ZVSA.O",999,"rich_text","ZVSA","Date","🧐 What is the current price-to-earnings ratio of ZyVersa Therapeutics after Q4 2024 earnings release?","📰 Were there any one-time expenses or restructuring costs in ZyVersa Therapeutics' Q4 2024 financials?","ths_ainvest_lite_web","progress\u002Fsearching_for",1000,"searching_for","R&D Expenses","llm_generated","auto","agent","ZVSA R&D Expenses, SG&A Expenses, CAPEX in Q4 2024",1746749648525,"dp95203100","inspect stocks","title1","code","fixed_index","abs_国际美股领域","Ticker","Name","aigc","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","In Q4 2024, ZyVersa Therapeutics saw a significant increase in Research and Development (R&D) expenses, which rose to $121,245. This indicates a strong focus on product development and innovation. However, there was no corresponding data for Change in Property and Equipment, which suggests that the company may not have made significant investments in physical assets during this period.\n\n\n|code|Ticker|Name|Date|R&D Expenses|market_code|\n|---|---|---|---|---|---|\n|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q1|512937|186|\n|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q2|709049|186|\n|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q3|436043|186|\n|ZVSA|ZVSA.O|ZyVersa Therapeutics|2024 Q4|121245|186|\n\n","select   stock_code,   r_d_expenses,   payments_for_property_and_equipment from   ustock_fin_data where   report_end_date = date('2024y4q')   and stock_code = 'ZVSA.O'","agent_common_v2\nagent-summary","normal_agent","NONE","stock","In Q4 2024, ZyVersa Therapeutics saw a significant increase in Research and Development (R&D) expenses, which rose to $121,245[^1]",". This indicates a strong focus on product development and innovation. However, there was no corresponding data for Change in Property and Equipment, which suggests that the company may not have made significant investments in physical assets during this period.\n\n","\n``` visual\n{\"uuid\":\"067c63bb-5202-46f6-bc20-6b6e9da64c87\"}\n```","result_page","bar3","ZVSA R&D Expenses","market_code","2+679_496_21_554+0+0+b823eed7-4562-4496-a34f-fc7bb25c1827+2ed47fc2938dacb65f23ec0f2aaafa3f+llm_generated+aimeTagAnalysis+0+0.011681740172207355+1","2+679_496_21_554+0+0+b823eed7-4562-4496-a34f-fc7bb25c1827+f89fe3cfb641e8d985ce8819c73d8946+llm_generated+aimeTagAnalysis+0+0.0030668892432004213+2","recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/195837b.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/e402278.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7c15041.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/69a864a.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/9579193.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/6726d3c.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/c69ce63.js" defer=""></script>